Cancer stem cell hypoxia and NF-κB signaling pathways (CSC/Hypoxia/NF-κB axis)

The Cancer stem cell hypoxia and NF-κB signaling pathways represent a complex regulatory network that governs the survival, self-renewal, and chemoresistance of cancer stem cells (CSCs) within the tumor microenvironment. This network is characterized by significant crosstalk between the Hypoxia-Inducible Factor (HIF) system, which responds to low oxygen levels, and the Nuclear Factor-kappa B (NF-κB) pathway, a master regulator of inflammation and cell survival (PubMed: 18292227). In many cancers, hypoxia activates NF-κB, which in turn can upregulate HIF-1α expression, creating a feed-forward loop that promotes tumor progression and immune evasion (PubMed: 24651013). Therapeutic strategies targeting this axis often involve small molecule inhibitors of HIF or NF-κB components, such as belzutifan or bortezomib, though the broad physiological roles of these pathways present significant challenges for selective targeting (PubMed: 20147445). Because this term encompasses multiple distinct proteins and biological processes rather than a single molecular entity, it is classified as a pathway-level therapeutic theme. Targeting this axis aims to eliminate the resilient CSC population and overcome therapy resistance in various malignancies (Nature Reviews Cancer: 10.1038/nrc3130).

Other names

CSC-hypoxia-NF-κB axisHypoxia-NF-κB signaling crosstalkTumor microenvironment signaling pathwaysStemness-related hypoxia signaling

Inhibition of HIF-1α or HIF-2α activity, inhibition of IκB kinase (IKK) complex, or disruption of the transcriptional activity of the p65/p50 NF-κB heterodimer.